STALLERGENES has a total of 38 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2001. It filed its patents most often in EPO (European Patent Office), United States and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OFFENTLICHEN RECHTS, MEDINNOVA GES MED INNOVATIONEN and PROTEOLOGICS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 15 | |
#2 | United States | 8 | |
#3 | Australia | 5 | |
#4 | WIPO (World Intellectual Property Organization) | 4 | |
#5 | Hungary | 2 | |
#6 | EAPO (Eurasian Patent Organization) | 1 | |
#7 | France | 1 | |
#8 | Japan | 1 | |
#9 | Slovenia | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Basic materials chemistry | |
#6 | Agriculture |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Peptides | |
#5 | Microorganisms | |
#6 | Measuring microorganism processes | |
#7 | Sugars | |
#8 | Fermentation | |
#9 | Animal care | |
#10 | Preservation of human bodies |
# | Name | Total Patents |
---|---|---|
#1 | Moingeon Philippe | 31 |
#2 | Nony Emmanuel | 15 |
#3 | Batard Thierry | 13 |
#4 | Mascarell Laurent | 11 |
#5 | Bodo Véronique | 10 |
#6 | Bouley Julien | 8 |
#7 | Lombardi Vincent | 6 |
#8 | Villet Bertrand | 6 |
#9 | Gueguen Claire | 5 |
#10 | Razafindratsita Alain | 4 |
Publication | Filing date | Title |
---|---|---|
US2019024177A1 | Il-10 as a predictive biomarker of responsiveness to house dust mite allergen immunotherapy | |
US2017370946A1 | Sialylated fetuin-A as a marker of immunotherapy efficacy | |
WO2016066770A1 | Markers of immune response | |
EP2974741A1 | Composition of allergen extracts having reduced toxicity and method of production thereof | |
EP2281456A1 | Process for preparing raw pollen | |
EP2427497A2 | Use of igg1 immunoglobulins and/or ligands of the cd32 receptor for treating inflammatory diseases and incidents via the mucosa | |
EP1908777A1 | Mite fusion proteins |